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Abstract
A validated method for assessing hemostasis in vivo is critical for testing the hemostatic efficacy
of therapeutic agents in preclinical animal models and in patients with inherited bleeding
disorders, such as von Willebrand disease (VWD) and hemophilia A, or with acquired bleeding
disorders such as those resulting from medications or disease processes. In this review, we discuss
current methods for assessing hemostasis in vivo and the associated challenges. We also present
ARFI-Monitored Hemostatic Challenge; a new, potentially alternate method for in vivo hemostasis
monitoring that is in development by our group.
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Introduction
Bleeding is a frequent and deadly complication of hematologic and cardiovascular disorders
- inherited or acquired. Inherited bleeding disorders, such as von Willebrand disease (VWD)
and hemophilia A, result from genetic deficiencies in plasma coagulation proteins and must
be managed by life-long intravenous infusion of therapeutic clotting factor replacement
products [1]. For plasma-derived products, despite the introduction of viral inactivation
techniques that have eliminated the risk of HIV transmission, there are ongoing concerns
about other transmissible agents (e.g., prions) that may not be eliminated [2–7]. Fortunately,
the risk of infection from recombinant products seems negligible. Acquired bleeding
disorders most frequently arise in subjects with atherothrombotic disease from the combined
use of currently approved anticoagulant (Coumadin, dabigatran etexilate, rivaroxaban), and
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antiplatelet (aspirin, clopidogrel, prasugrel) agents. This complication is likely to become
even more prevalent with the aging population, and it accounts for a majority of drug-related
emergency hospitalizations [8]. While vitamin K or plasma products can reverse Coumadin's
effect and are routinely used to treat or prevent bleeding associated with Coumadin use, the
rapidly growing number of antithrombotic agents with no proven reversal therapies
constitute a common clinical challenge, and major hemorrhage is arguably now the rate-
limiting step in the development of even more effective antithrombotic strategies.
Fortunately, innovative approaches such as gene therapy and protein engineering [9–11] are
in development to control bleeding from VWD and hemophilia. The novel proteins such as
recombinant factor VIIa (rFVIIa) are also often used to reverse bleeding due to
antithrombotic therapy. This choice is in part because current expert statements on the
management of bleeding induced by established and emerging anticoagulants usually
include a suggestion to use rFVIIa [12,13], despite the paucity of clinical evidence or pre-
clinical data to support this recommendation [14,15]. However, translating these approaches
to clinical trials requires a reliable diagnostic test that directly detects early bleeding and
confirms hemostasis in vivo.
Plasma and Whole Blood -Based Coagulation Factor Activity Assays
Importantly, plasma-based coagulation factor activity assays are helpful surrogates for
hemostasis but do not directly measure hemostasis in vivo. These include the standard aPTT
[16], two stage and chromogenic assays. Whole blood-based assays include the whole blood
clotting time (WBCT) which is a modification of the Lee-White clotting time using two
siliconized glass tubes (Vacutainer™ #6431, Becton-Dickinson, Rutherford, NJ) in a 28 °C
water bath [17,18]. One ml of whole blood is drawn and 0.5 ml blood is distributed into each
dry tube. A timer is started. After one minute, one tube is tilted every 30 sec, the other left
undisturbed. When a clot forms in the tilted tube, the second tube is then tilted every 30 sec
until a clot forms. The time for formation of a fully gelled clot in the second tube is recorded
as the WBCT.
Current In Vivo Hemostasis Assays in Large Animal Models
Pre-clinically, conventional in vivo tests to assess the hemostatic efficacy of therapeutic
agents include the primary saline bleeding time (1°SBT) in VWD dogs and the primary
cuticle bleeding time [19,20], the gingival biopsy bleeding time [21], and the secondary
cuticle bleeding time (2° CBT) [22–24] in hemophilia A dogs. Several variations of the
primary bleeding time have been used to detect disorders of primary hemostasis such as von
Willebrand disease (VWD) [25,26] and monitor the response to therapy. We have used the
1°SBT described by Mertz [27] in canine and porcine models of type 3 VWD [9,28]. This
test is done with the tip of the ear immersed in 37 °C 0.9% saline for 2 minutes, then the tip
is transfixed with a scalpel blade over ~0.5 cm, the cut ear tip is resub-merged in the warm
saline, and the time to cessation of bleeding is recorded. A normal value is defined as <5
minutes and abnormal value is defined as >15 minutes. In the primary and secondary cuticle
bleeding time tests, excess hair is shaved away from the toe and the paw is immersed in 37
°C 0.9% saline for 2 minutes. Using a guillotine-type of nail cutter, the primary cut is made
at the juncture of the nail with the nail bed or “quick.” The bleeding nail is immersed in 37
°C 0.9% saline and the endpoint is the time that bleeding convincingly stops for a full
minute and is called the Primary Cuticle Bleeding Time [19,20]. For the Secondary Cuticle
Bleeding Time, the injured surface is subjected to a second guillotine cut 2 hours after the
first, the bleeding nail is again immersed in 37 °C 0.9% saline, bleeding is visually
monitored and the endpoint is the time that bleeding convincingly stops for a full minute
[29–32]. For gingival or buccal mucosa bleeding time tests, various methods for wounding
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oral mucosa to induce bleeding have been described and, in general, the time to cessation of
bleeding is reported as the gingival or buccal mucosa bleeding time [21,26,33].
Despite many years of use, significant problems with reproducibility persist for these current
in vivo tests. Table 1 shows results of performing the 1° SBT [27,34], in 11 dogs with VWD
and the 2° CBT in 20 dogs with hemophilia A [9,28]. Recall a normal value is defined as <5
min, and abnormal value is defined as >15 min. The 1° SBT was >15 min in 7/11 dogs on
the first try, reproducible in only 4 of these 7, and excessive bleeding and unclear endpoints
were common due to waxing and waning rates of bleeding (row a). The 2° CBT was >15
min on the first attempt in fewer than half the animals tested, the test was reproducibly long
in only half the dogs tested twice, and four dogs had excessive bleeding that necessitated
stopping the test prematurely. Eight dogs also had unclear endpoints due to the sudden
resurgence of bleeding immediately after stopping or appearing to stop (row b). Additional
complications included inadequate anatomy for the prescribed cuticle incisions and dogs
licking, scratching and ambulating during the observation period. The inherent variability in
both 1° SBT and 2° CBT requires screening and exclusion of many dogs from entering
studies, necessitating use of more animals. Moreover, as these tests involve monitoring
bleeding from induced injury at the nail cuticle or ear tip, neither assesses a clinically
relevant bleeding location or hemostatic challenge.
Novel ARFI-Monitored Hemostatic Challenge
We have recently developed the ARFI-Monitored Hemostatic Challenge, in which bleeding
response to a peripheral vascular puncture is monitored by Acoustic Radiation Force
Impulse (ARFI) imaging methods. ARFI ultrasound noninvasively differentiates tissue
mechanical properties by tracking dynamic tissue displacement in response to impulsive
acoustic radiation force excitation [35]. A detailed description of the ARFI-Monitored
Hemostatic Challenge is provided in [36]. Notably, the ultrasound transducer is positioned
above a punctured peripheral vessel (Fig. 1) and custom software is used to isolate blood
pixels from the surrounding soft tissue pixels. Once blood pixels are identified, the cross-
sectional area of hemorrhage can be measured in each of several serially acquired ARFI
images, from which bleeding rate (BR) and time to hemostasis (TTH) are assessed, as
shown in Fig. 2.
Pre-clinically, the ARFI-Monitored Hemostatic Challenge is implemented by puncturing
capillaries and a small (~2 mm diameter) vein in hind limb muscle approximately 2 cm
below the skin surface [36]. Table 2 shows the BR and TTH results of performing the ARFI-
Monitored Hemostatic Challenge in the following series of dogs: normal (n=6), naïve
hemophilia A monitored for 30 minutes of bleeding then infused with canine FVIII to
11.3±1.8% activity (n=8) to prevent formation of large hematomas, hemophilia A
expressing canine factor FVIIa at 1.3–2 μg/ml (cFVIIa, n=3) [37], naïve VWD (n=6), and
VWD infused with von Willebrand Factor (VWF) to a level of 7.1±1.7% of normal
VWF:Ag (n=4). Relative to abnormal primary hemostasis, ARFI-derived BR was markedly
increased in naïve VWD dogs compared to normal dogs by a factor of ~2. Note that
prophylactic infusion of VWF from <1% to a level of 7.1±1.7% of normal VWF: Ag was
associated with a mean ARFI-derived bleeding rate of less than one-third that in naïve VWD
and not statistically significantly different than normal. FVIII activity (Coamatic FVIII
activity, Chromogenix), historically higher in VWD dogs than type 3 VWD humans [38],
was 64±7.4 pre and 57±22.4 post infusion expressed as a % of normal canine plasma. These
FVIII activity levels strongly suggest that this reduction in bleeding rate is due to correction
of a VWF-mediated platelet defect of primary hemostasis and not FVIII deficiency. Mean
ARFI-derived TTH in naïve and prophylactically-treated VWD dogs were not significantly
different than normal.
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Relative to abnormal secondary hemostasis, ARFI-derived TTH was significantly longer in
naive hemophilia A compared to normal dogs. Administration of FVIII to 11.3±1.8%
(Coamatic FVIII activity, Chromogenix) in an “on-demand” fashion to treat the bleeding
hemophilia A dogs shortened the time to hemostasis, but the difference was significant
relative to normal dogs. Notably, transgene expression of canine FVIIa at 1.3 – 2 μg/ml (a
therapeutic level) [37] shortened the time to hemostasis relative to naïve hemophilia A and
was not significantly different than normal. ARFI-derived bleeding rates calculated over the
first 30 min following puncture were not significantly different between normal, naïve
hemophilia A, hemophilia A treated with FVIII “on-demand”, or hemophilia A dogs
expressing cFVIIa.
The data of Table 2 demonstrate that ARFI Monitored hemostatic Challenge yields
outcomes that are consistent with expectations for the various bleeding phenotypes and
associated treatments examined: 1) statistically significantly faster rates of bleeding in von
Willebrand's disease, a disorder of primary hemostasis, 2), statistically significantly longer
times to hemostasis in hemophilia A, a disorder of secondary hemostasis, and 3) full or
partial correction of bleeding phenotype with treatment. Taken together, these data strongly
support that ARFI-Monitored Hemostatic Challenge is relevant for assessing hemostasis and
responses to treatment in vivo in inherited disorders of both primary and secondary
hemostasis. In order to develop the ARFI-Monitored Hemostatic Challenge as a validated in
vivo hemostasis assay, its accuracy and reproducibility must be established. While not yet
completed at the time of publication, these properties are being assessed. We have not
systematically looked at complications, but they appear limited to a small hematoma (<2
cm). In addition, no dog has required additional blood products after completion of the
experimental protocol. Although we have only applied our methods on relevant dog models
pre-clinically, we believe they are applicable to murine models for VWD and Hemophilia as
well and could be modified to use higher frequency equipment specifically designed for
small animal imaging.
Clinical ARFI-Monitored Hemostatic Challenge
Using methods very similar to those described in its pre-clinical application, the ARFI-
Monitored Hemostatic Challenge was applied clinically to assess hemostasis at femoral
arteriotomy [39]. Twenty adult patient volunteers undergoing percutaneous diagnostic
cardiac catheterization requiring femoral artery access were enrolled from the Cardiac
Catheterization Laboratory in UNC Hospitals. The ultra-sound scanner was wheeled to the
patient bed-side after completion of the catheterization procedure, and the imaging
transducer was centered above the femoral arteriotomy, with the puncture path from the skin
surface to the arteriotomy in the imaging field of view. The subjects underwent ARFI
monitoring at the femoral arteriotomy site for a 15 min observation period immediately
following sheath removal. Ten patients were treated with standard of care manual
compression to the femoral arteriotomy alone, and ten were treated with manual
compression augmented by a hemostatic dressing reported to decrease times to hemostasis
by approximately 37% [40–42]. Table 3 shows the ARFI-derived BR, calculated over five-
minute intervals, and ARFI-derived TTH in the two patient populations. In both patient
groups, ARFI-derived BR decreased with time following sheath removal. Moreover,
bleeding rates in each time interval were lower in the group treated with manual
compression augmented by a hemostatic dressing compared to manual compression alone.
ARFI-derived times to hemostasis were also shorter in the hemostatic dressing group.
The data of Table 3 show that ARFI Monitored Hemostatic Challenge yields outcomes that
are consistent with expectation for the use of a hemostastic dressing to augment manual
compression: 1) statistically significantly slower bleeding rates, and 2) statistically
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significantly faster time to hemostasis in patients treated with the hemostastic dressing
versus standard of care manual compression alone. These preliminary clinical data in non-
anticoagulated patients strongly suggest that ARFI monitoring of femoral arteriotomy site in
patients receiving anti-platelet and anticoagulant therapy will be a valid assay for bleeding
phenotype in patients with acquired bleeding disorders.
Conclusion
The primary saline bleeding time and the secondary cuticle bleeding time have historically
been used to document hemostatic efficacy in vivo in dogs with VWD and hemophilia. Both
tests are difficult to reproduce in a given dog and vary greatly among dogs. Preliminary data
supports that the ARFI-Monitored Hemostatic Challenge is a viable imaging method for in
vivo detection of rate of bleeding and onset of hemostasis following a standardized
hemostatic challenge in these animals as well as in humans undergoing femoral arteriotomy.
On-going work aims to establish the reproducibility and clarity of ARFI-Monitored
Hemostatic Challenge end points and describe any associated complications.
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The ultrasound transducer, held in place with a stereotactic clamp, is positioned above a
peripheral vessel.
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Methods of Bleeding Rate and Time to Hemostasis Estimation using ARFI-Monitored
Hemostatic Challenge – (bottom row) In serially acquired ARFI frames in a naïve
hemophilia A dog, hemorrhage pixels (red) are identified [36] and associated cross-sectional
area (CSA) calculated. (top graph) CSA is plotted versus time of image acquisition (blue
dots). The CSA plot is subdivided into (in this example, 10 min) intervals, and a line is fit
using a linear least-squares regression approximation (red lines). The slopes of the lines are
recorded as the bleeding rate [mm2/min]. Time to hemostasis onset is estimated as time to
75% of the maximum observed hemorrhage CSA. FVIII was given at 30 min to 11.3±1.8%
of normal.
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Table 1
Lack of Reproducibility of the Primary Saline Bleeding Time (1°SBT) in VWD dogs (a) and of the Secondary
Cuticle Bleeding Times (2°CBT) in Hemophilia A Dogs (b).
>15 min on 1st try Reproducible Excessive Bleeding Unclear endpoints
*
a. VWD dogs (n = 11) 7/11 4/7 4/11 7/11
b. Hemophilia A (n = 20) 8/20 4/8 4/20 8/20
*
bleeding slowed to almost zero then suddenly increased during observation period.
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Table 2
ARFI-Monitored Hemostatic Challenge Bleeding Rates & Times to Hemostasis by Dog Phenotype.
Hemostasis Phenotype Dog Genotype n Mean Bleeding Rate (mm2/min) Mean Time to Hemostasis (min)
*
Normal Hemostasis



































ARFI Time to Hemostasis is defined as that required to bleed 75% of the total detected area of hemorrhage.
†
Mean from two separate procedures on each dog. No additional plasma therapy was required in these dogs.
#
Mean Bleeding Rate comparisons 1 vs 2 p<0.111, 1 vs 3 p<0.520, 1 vs 4 p<0.492, 1 vs 5 p<0.00003, 1 vs 6 p = 0.523, 5 vs 6 p = 0.00024.
§
Time to Hemostasis comparisons 1 vs 2 p<0.00078, 1 vs 3 p<0.027, 1 vs 4 p<0.057, 2 vs 4 p<0.01, 1 vs 5 p = 0.166, 1 vs 6 p = 0.566, 5 vs 6 p =
0.137.
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Table 3
Clinical Bleeding Rates & Time to Hemostasis from ARFI-Monitored Hemostatic Challenge by Treatment
Type.
Group n Bleeding Rate (mm2/min)
Time To Hemostasis (min) (4)






















within manual compression group comparisons: 1 vs 2 p<0.136; 1 vs 3 p<0.006.
ξ
within hemostasis dressing group comparisons: 1 vs 2 p<0.006; 1 vs 3 p<0.00009.
ψ
between group comparisons: 1:1 p<0.013; 2:2 p<0.02; 3:3 p<0.00001; 4:4 p<0.0046.
†
one patient excluded due to motion artifact.
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